Now that we have demonstrated the potent immunosuppressive function of Neu2, the effect of CTCF-MIEN1-IL-1β signaling on anti-PD-L1 therapy in CRC was investigated, both in primary tumors and liver metastases. The gene discussed is NEU2; the disease is colorectal carcinoma.